The VEGFR3/FLT4 receptor, which is involved in vasculogenesis and angiogenesis, binds and phosphorylates SHC proteins on tyrosine residues. SHC contains two phosphotyrosine interaction domains: a PTB (Phosphotyrosine Binding) and a SH2 (Src Homology 2) domain. Previous studies have shown that SHC proteins are phosphorylated on Y239/Y240 and Y313 (Y317 in humans) by tyrosine kinases such as the EGF and IL3 receptors. We have investigated which of the SHC tyrosine residues are targeted by the VEGFR3/ FLT4 kinase and the role of the SHC PTB and SH2 domains in this process. Our results show that Y239/ Y240 and Y313 are simultaneously phosphorylated by the kinase, creating GRB2 binding sites. Mutation of SHC PTB, but not SH2, domain interferes with the SHC phosphorylation by VEGFR3/FLT4. Soft agar assay experiments revealed that the VEGFR3/FLT4 transforming capacity is increased by the mutation of Y239/Y240 to phenylalanines in SHC, suggesting that these two residues mediate an inhibitory signal for cell growth. Mutation of the two phosphorylation sites increases this eect, suggesting that they have a synergistic role.
Introduction
Receptor tyrosine kinases (RTK) signal transduction follows a series of conserved steps regardless of the class of receptor. Ligand binding to the RTK extracellular domain leads to receptor oligomerization and autophosphorylation on multiple tyrosine residues. These tyrosine autophosphorylation sites serve as binding sites for SH2 and PTB domain containing proteins. The RAS pathway represents one of the best understood cascade after RTK activation because both genetic and biochemical approaches have led to the same conceptualization of the system. After receptor activation, the SH2 domain containing protein GRB2 binds to phosphorylated tyrosines resulting in recruitment of the GRB2-SOS complex at the plasma membrane where SOS, a GDP-GTP exchange factor, enhances the formation of GTP-bound RAS. This event triggers activation of the MAPK cascade leading to downstream events responsible for receptor biological activity (Rozakis-Adcock et al., 1992) .
GRB2 is an adaptor protein comprised of an SH2 domain¯anked by two SH3 domains. SH2 domains interact with phosphotyrosine containing proteins with a speci®city brought about by amino acids lying carboxy-terminal to the phosphotyrosine. The GRB2 SH2 domain binding consensus is a Y(p)XN where Y(p) is a phosphotyrosine, X is any amino acid and N is an asparagine (Songyang et al., 1994) . GRB2 is able to bind directly to phosphorylated RTKs but can also use other adaptors containing a Y(p)XN motif such as SHC and IRS1 docking proteins (Rozakis-Adcock et al., 1992; Myers et al., 1994) .
The SHC gene encodes three protein isoforms of 66, 52 and 46 kD arising from both alternative splicing and translational start sites . SHC contains two phosphotyrosine interaction domains: an amino-terminal PTB domain and a carboxy-terminal SH2 domain, that¯ank a proline/serine rich region, the collagen homology region (CH1). The SHC PTB domain binds to a YXNPXY(p) sequence found in RTKs, cytokine receptors and SHIP, a phosphatidylinositol phosphatase (Kavanaugh and Williams, 1994; Blaikie et al., 1994; Songyang et al., 1994) . The SHC SH2 domain binds to Y(p)XXL/V/M sequences found in EGF-Receptor and CD3z (Songyang et al., 1994) . Mutagenic and structural data emphasize the role of critical residues found in SH2 and PTB domains. The mutation of the arginine (R) to lysine (K) lying in a highly conserved FLVR motif of SH2 domains completely abrogates the interaction of the SH2 domain with phosphotyrosine targets Waksman et al., 1992) . A phenylalanine present in the carboxy-terminal alpha helix of SHC PTB domain appears as crucial for binding to peptides. Mutation of this phenylalanine to valine (F198V mutation) eliminates the interaction of SHC with EGF receptor and Insulin receptor (Zhou et al., 1995a; Yajnik et al., 1996; Isako et al., 1996) . Functional studies with SHC interaction domains suggest that the PTB domain integrity is required for binding to receptors and subsequent SHC phosphorylation whereas the SHC SH2 domain is important for later events. Experiments with dominant negative proteins have also shown that expression of isolated domains inhibits EGF receptor, Insulin receptor and polyoma virus middle T antigen (MTAg) mitogenic activity (Ricketts et al., 1996; Blaikie et al., 1997; Gotoh et al., 1997; Thomas and Bradshaw, 1997) .
SHC is a substrate for many tyrosine kinases McGlade et al., 1992; Pronk et al., 1993; Dilworth et al., 1994; Liu et al., 1994; VanderKuur et al., 1995; Damen et al., 1996; Chen et al., 1996) . Tyrosine Y313 in murine SHC -Y317 in human SHCin the CH1 region, was for a long time believed to be the unique site of tyrosine phosphorylation and sole GRB2 binding site. More recent data have shown that a tandem of tyrosines (Y239/Y240) present in the CH1 region is phosphorylated following EGF or IL3 stimulation and represents an additional high anity GRB2 binding site. Y239/Y240 and Y313 may mediate dierent signal to the nucleus (Gotoh et al., 1996 (Gotoh et al., , 1997 van der Geer et al., 1996; Harmer and DeFranco, 1997) . Both Y239 and Y240 can be either equally phosphorylated or with dierent kinetics or at dierent levels, depending on the stimulus (Harmer and DeFranco, 1997; Gotoh et al., 1997) The VEGFR3/ FLT4 receptor belongs to the family of VEGF receptors. These RTKs are involved in angiogenesis and vasculogenesis (Pajusola et al., 1992; Galland et al., 1992; Mustonen and Alitalo, 1995; Korpelainen and Alitalo, 1998) . The human FLT4 gene encodes two protein isoforms, FLT4L (long form) and FLT4S (short form), by alternative splicing. Although both forms seem to be expressed in the same tissues (Fournier et al., 1995) , it is not known whether they are coexpressed in the same cell. Only FLT4L is endowed with transforming activity. FLT4L binds the VEGFc and VEGFd ligands and can promote proliferation of endothelial and ®broblast cells (Pajusola et al., 1994; Borg et al., 1995; Joukov et al., 1996; Lee et al., 1996; Achen et al., 1998) . The FLT4L cytoplasmic region binds directly GRB2 but a second pool of GRB2 is also recruited by the receptor through its interaction with SHC (Pajusola et al., 1994; Borg et al., 1995) . We have previously shown that SHC binds FLT4L through both its PTB and SH2 domains. The FLT4L receptor contains a SHC PTB binding site in its carboxyterminal region and mutation of this site abrogates its in vitro transforming activity. This mutation alters SHC phosphorylation and the formation of SHC-GRB2 complex (Fournier et al., 1995 (Fournier et al., , 1996 .
We have investigated which of the two sites of SHC tyrosine phosphorylation is targeted by FLT4L and which of SH2 or PTB domains of SHC is required for SHC phosphorylation by FLT4L. Using site-directed mutagenesis of interaction domains and tyrosine residues of SHC, we demonstrate that the FLT4L kinase targets both Y239/Y240 and Y313 to create two GRB2 binding sites in SHC. Furthermore, we show that the PTB domain but not the SH2 domain is required for SHC phosphorylation. Surprisingly, mutations of Y239/ Y240 to phenylalanines considerably increase FLT4L transforming activity suggesting that a negative signal originates from the Y239/Y240 tandem.
Results

Tyrosine phosphorylation of SHC by FLT4L
FLT4L oligomerization provokes a rapid and intense SHC tyrosine phosphorylation (Pajusola et al., 1994; Fournier et al., 1995) . To identify the sites of SHC tyrosine phosphorylation, we used a previously described epitope myc-tagged SHC construct, which allows detection of both p52 and p46 SHC proteins but not endogenous SHC (Figure 1a ) . This construct was cloned into the pBABE retroviral vector that confers puromycin-resistance to infected cells (Morgenstern and Land, 1990) . We mutated the sites of tyrosine phosphorylation in SHC (Y239, Y240 and Y313 mutated to phenylalalanine) and the residues crucial for PTB (mutant F198 to V198) and SH2 (mutant R397 to K397) domain function. Truncated SHC (PTB and PTB+Y239/Y240) were tagged in amino-terminal position.
RAT2 cells stably expressing a chimeric FMS/ FLT4L receptor (FF4L RAT2 cells) were infected with supernatants from Gp + E packaging cell line and selected in puromycin-containing medium . Total lysates (TL) of dierent puromycinresistant populations were run on an SDS-gel and, after Western blot, the membrane was probed with anti myc antibody. Figure 1b shows that myc-tagged SHC proteins were detected in each type of pBABE-SHC (but not pBABE) infected cells.
Cell populations expressing myc-tagged SHC proteins were then stimulated with medium or medium supplemented with CSF1 before lysis and proteins were immunoprecipitated with anti myc antibody, immune complexes separated by SDS-gel and transferred onto nitrocellulose. The membrane was probed with anti SHC (upper panel), anti PY (middle panel) and anti myc (lower panel) antibodies ( Figure 1c ). Although a constitutive phosphorylation of SHC was observed in unstimulated cells due to basal activation of FLT4L , the addition of CSF1 markedly increased SHC tyrosine phosphorylation (middle panel). Stripping of the membrane and probing with anti GRB2 antibody showed that GRB2 binding to SHC correlates with SHC tyrosine phosphorylation (data not shown and see below). These results are in agreement with previous observations obtained with endogenously expressed SHC (Pajusola et al., 1994; Fournier et al., 1995; Wang et al., 1996) .
Y313 and Y239/Y240 tyrosines of SHC are targeted by FLT4L
SHC contains two major sites of tyrosine phosphorylation, Y239/Y240 and Y313, located in the CH1 region ( Figure 1a ). Both sites are GRB2 binding sites (Gotoh et al., 1996 (Gotoh et al., , 1997 van der Geer et al., 1996; Harmer and DeFranco, 1997) . To determine whether one of these sites is preferentially phosphorylated after FLT4L activation, we mutated each tyrosine to phenylalanine and expressed the SHC mutants in FF4L RAT2 cells. Immunoprecipitation by anti myc antibody and immunoblotting by anti PY antibody were then done on lysates from unstimulated or stimulated cells: the Y239F/Y240F mutation as well as the Y313F mutation showed decreased SHC tyrosine phosphorylation whereas the triple mutation Y239F/Y240F/Y313F (mutant SHC Y3F) completely eliminated SHC tyrosine phosphorylation (Figure 2 upper panel -the upper band represents p52 SHC; p46 SHC appears in a background of revealed immunoglobulin chains from the mouse monoclonal anti myc antibody). It is worth to note that the level of phosphorylation of SHC was higher in Y313F than in Y239F/Y240F. This suggests that both Y239 and Y240 can be phosphorylated after stimulation, while only one tyrosine residue, Y313, remains phosphorylated in Y239F/Y240F. Stripping and reprobing of the membrane with anti GRB2 antibody con®rmed that Y239/Y240 and Y313 are GRB2 binding sites (not shown and see Figure 3 ). These experiments show that FLT4L targets both Y239/Y240 and Y313 of SHC.
Time course of SHC tyrosine phosphorylation following FLT4L activation
We next analysed the time course of SHC tyrosine phosphorylation following FLT4L activation. Cells were treated with CSF1 for dierent times and SHC proteins were immunoprecipitated with anti myc antibody. As previously described with endogenous Figure 1 Schematic representation and expression of SHC constructs (A) The p52 SHC protein contains a PTB and a SH2 domain separated by a collagen homology region (CH1). Y239, Y240 and Y313 are the three tyrosine residues phosphorylated by tyrosine kinases. Each tyrosine was mutated to phenylalanine (F) alone or in combination. SHC PTB+Y239/Y240 and SHC PTB are truncated proteins containing the PTB domain with (SHC PTB+Y239/Y240) or without ( SHC PTB) the Y239/Y240 tandem. All cDNAs were cloned into the pBABE retroviral vector allowing expression of myc-tagged proteins. (B) A RAT2 cell line stably expressing FMS/FLT4L chimera (FF4L) was infected with Gp+E supernatants resulting in expression of the various constructs. Resistant populations were lysed and extracted proteins were subjected to Western blot. Membranes are blotted by anti FLT4 (upper panel) or anti myc (lower panel) antibodies to show similar amounts of protein in cells. Expression of PTB and SH2 domains mutants are shown in Figure 4 . (C) FF4L puromycin-resistant populations infected by vector alone (pBABE) or pBABE-SHC supernatants were either left unstimulated (7) or stimulated for 5 min with 0.5 mg/ml of CSF1 (+). Extracted proteins were immunoprecipitated with anti myc or anti SHC antibody and were subjected to Western blot. Proteins were revealed with anti SHC, anti PY or anti myc antibodies A SHC phosphorylation and VEGFR3 E Fournier et al SHC (Fournier et al., 1995) , epitope-tagged SHC proteins were phosphorylated after 2 min (Figure 3 , middle panel). Identical kinetics were observed with SHC Y239F/Y240F and Y313F mutants, suggesting comparable phosphorylation of these tyrosines by the kinase. No SHC phosphorylation could be detected in SHC Y3F mutant. In each case, GRB2 binding correlated strictly with SHC phosphorylation ( Figure  3, lower panel) . We conclude from these data that SHC proteins are simultaneously phosphorylated on Y239/ Y240 and Y313 following FLT4L activation, and that both Y239/Y240 and Y313 are GRB2 binding sites.
Mutagenesis of SHC SH2 and PTB domains
The SHC PTB domain binds to a FYNSE(p)Y1337 motif found in the carboxy-terminal region of FLT4L. This sequence ®ts with the canonical SHC PTB binding site YXNXX(p)Y (Songyang et al., 1994) . A phosphopeptide encompassing this motif is able to bind SHC in a PTB-dependent manner (Fournier et al., 1996) . Several residues involved in phosphopeptide interaction have been described in the SHC PTB domain. One group contains residues complexing the phosphotyrosine: two arginines (R67 and R175) and a serine (S151). A second group is represented by a phenylalanine (F198) present in the carboxy-terminal alpha helix of SHC PTB domain which contacts residues of the 75 (Y) and 73 (N) position relative to the phosphotyrosine. Mutations R175Q or F198V abrogate the binding of SHC PTB domain to its target (Zhou et al., 1995b; Yajnik et al., 1996; Isako et al., 1996) .
We expressed F198V SHC mutant in FF4L RAT2 cells and measured the eect of this mutation on SHC phosphorylation. Although a basal SHC phosphorylation was observed, this mutation abrogated further SHC tyrosine phosphorylation by CSF1 (Figure 4 , lower panel, sixth lane). This result con®rms that the SHC PTB domain is important for SHC phosphorylation by FLT4L (Fournier et al., 1996) . As the SHC SH2 domain also contacts activated FLT4L (Pajusola et al., 1994; Borg et al., 1995) , a conserved arginine (R397) was mutated to lysine (K) within this domain (mutant R397K). This mutation did not aect SHC tyrosine phosphorylation (Figure 4 , lower panel, last lane). Thus, the PTB domain of SHC but not its SH2 domain, is required for ligand-induced SHC tyrosine phosphorylation by FLT4L.
Transforming activity of FLT4L is increased by Y239F/ Y240F mutations FLT4L transforming activity has previously been observed in a soft agar assay. Colony growth depends strictly on the addition of ligand and correlates with SHC tyrosine phosphorylation . This functional assay was done to evaluate the eects of SHC mutants on FLT4L behavior.
Overexpression of SHC did not increase the eciency of FLT4L transforming activity as the number of colonies were comparable in cells infected with mock virus (pBABE) and cells infected with virus allowing expression of myc-tagged SHC ( Figure 5 ). Mutation Y313F weakly aected the growth of colonies in CSF1-containing wells whereas the Y239F/Y240F mutation increased the number of colonies at 0.5 mg/ml of CSF1 ( Figure 5 ). Triple mutant SHC Y3F had a phenotype similar to SHC Y239F/Y240F mutant but a greater eect, visible at the lower CSF1 concentrations, something never observed with other cells. SHC Y239F/Y240F and SHC Y3F mutants were not transforming by themselves because no colonies arose without CSF1. Furthermore, expression of SHC Y3F in FF4S RAT2 cells (a FLT4 receptor devoid of transforming activity and SHC PTB domain binding site) did not induce the growth of colonies. Thus, both FLT4L activity and FLT4L-SHC interaction are important for the Figure 4 Mutation of the SHC PTB domain decreases SHC tyrosine phosphorylation. Mutants of SHC PTB domain (F198V) or SH2 domain (R397K) were expressed in FF4L clone and resistant populations were either left unstimulated (7) or stimulated (+) with CSF1. After immunoprecipitation with anti myc antibody, proteins were revealed with anti myc or anti PY antibodies Results are from one soft agar plating but are representative of three separate experiments. Number of colonies for RAT2 FF4L infected with mock virus (pBABE) seeded in wells containing 0.5 mg/ml of CSF1 is considered as a 100 index increased transforming activity of SHC Y239F/Y240F and Y3F mutants.
As additional controls, we expressed truncated SHC mutants in FF4L RAT2 cells (Figure 1) . SHC PTB+Y239/Y240 protein encompasses Y239/Y240 whereas SHC PTB protein ends just before the two tyrosines. SHC PTB+Y239/Y240, but not SHC PTB protein is tyrosine phosphorylated, and is able to bind GRB2 after FLT4L activation (data not shown). In a manner similar to SHC Y3F mutant, SHC PTB induces an increased transforming activity of FLT4L in the presence of ligand whereas SHC PTB+Y239/Y240 behavior resembles SHC overexpression ( Figure 5 ). Three separate experiments gave similar results : for a growth of FF4L pBABE cells counted as a background level of 100, the number of colonies of Y3F cells was then 4.76, 5.58 and 9.1 times more, respectively. Figure 5b shows a quantitation of the number of colonies in one of them.
In conclusion, although both Y239/Y240 and Y313 become phosphorylated by FLT4L and bind GRB2, mutation of Y239/Y240 induces a striking increase of transformation. Mutation of Y313 increases this eect although it induces no change by itself. We conclude from these data that the Y239/Y240 tandem initiates a negative signal for FLT4L transforming activity. This eect is enhanced by the Y313F mutation.
Discussion
This report focuses on the interaction between SHC proteins and the FLT4L receptor. Using epitope-myc tagged SHC proteins, we show that FLT4L kinase activity targets the two tyrosine phosphorylation sites of murine SHC, i.e. Y239/Y240 and Y313. Phosphorylation of these tyrosines creates high anity binding sites for GRB2 protein. We have also shown the importance of the SHC PTB and SH2 domains in FLT4L-mediated tyrosine phosphorylation of SHC. Our data show that the SH2 domain interaction is dispensable for SHC phosphorylation whereas the PTB domain appears crucial. This conclusion was drawn from speci®c missense mutations introduced within the respective interaction domains.
We tested the eects of SHC mutants in a soft agar assay. Although SHC proteins participate to the FLT4L-mediated transforming activity in a PTB domain-dependent manner (Fournier et al., 1996) , we did not observe a dominant-negative eect by expressing a SHC PTB domain (SHC PTB) alone or a triple mutant (SHC Y3F). In sharp contrast, we have previously shown that these constructs can eciently eliminate the in vitro transformation mediated by polyoma MTAg. In this system, only the SHC PTB domain and the Y239/Y240 tandem are required for transformation . The lack of dominant-negative eect observed in the FLT4L model may be explained by a low level of tagged proteins expression or by compensatory eects taking place in RAT2 cells. Myc-tagged SHC protein and its mutants are found associated with a FF4L-SOS complex in a CSF1-dependent fashion ( Figure 6 ). This result shows that FF4L is linked to the RAS pathway. It is unclear in the case of SHC Y3F protein how SOS participates to this complex since no GRB2 is found in the complex. The association is probably indirect through other protein complexes.
Surprisingly, we observed an enhanced transformation when SHC Y239F/Y240F or Y3F mutants were expressed in ®broblasts suggesting that the tandem of tyrosines mediates a negative signal. Y313 is believed to be the GRB2 binding site that couples SHC to the RAS pathway, whereas Y239/Y240 may activate an alternative pathway (Gotoh et al., 1996) . To date, only the GRB2 SH2 domain interaction with phosphorylated SHC Y239/Y240 has been demonstrated but interactions with other SH2 domain-containing proteins are conceivable, and it is possible that these proteins transduce a negative signal in cells (van der Geer et al., 1996) . The enhancement of transformation was greater with Y3F than with Y239F/Y240F, suggesting the existence of a synergistic eect between Y239/Y240 and Y313.
When expressed alone, the SHC PTB domain results in an increase in transformation whereas overexpression of a larger protein encompassing the Y239/Y240 motif (SHC PTB+Y239/Y240) shows no signi®cant dierence when compared to the full length protein.
Once again the Y239/Y240 tandem appears to act as negative regulator of SHC-mediated functions. The SHC PTB binding site of FLT4L is important for SHC tyrosine phosphorylation and for the transforming activity mediated by this receptor. Indeed, mutation of the PTB binding site in FLT4L abrogates the growth of colonies in a soft agar assay (Fournier et al., 1996) . The increase of transformation by expression of the SHC PTB alone may be explained by the fact that mutation of the SHC PTB domain binding site in Figure 6 Myc-tagged SHC proteins coimmunoprecipitate with a FF4L-SOS complex. RAT2 FF4L cells expressing myc-tagged SHC proteins were stimulated with CSF1 and extracted proteins were immunoprecipitated with anti myc antibody. After Western blot, proteins were revealed with anti SOS (which recognizes both SOS1 and 2), anti myc and anti FLT4 antibodies FLT4L interferes only with the formation of FLT4L-SHC complex whereas overexpression of SHC PTB protein probably competes the binding of SHC with FLT4L but also with other proteins. For example, a likely target of SHC PTB domain is SHIP, a phosphatidylinositol phosphatase that inhibits the signaling mediated by Insulin and immune receptors like FcgRIIB (Lioubin et al., 1996; Ono et al., 1996; Deuter-Reinhard et al., 1997) . The expression of SHC PTB construct may disrupt the pool of SHIP-SHC complex and interfere with the inhibitory signaling of SHIP. It is noteworthy that SHC is able to coimmunoprecipitate with a tyrosine-phosphorylated 120 ± 140 kD protein after FLT4L activation, a size similar to SHIP protein family (Pajusola et al., 1994) . Further experiments will determine if SHIP protein family members are involved in FLT4L signaling. Finally, p66, one of the three SHC isoforms, has been recently shown to inhibit the signaling mediated by receptors (Migliaccio et al., 1997; Okada et al., 1997) . It is thus possible that SHC PTB protein aects an inhibitory signaling mediated by p66 during FLT4L activation. SHC has been previously described as an adaptor protein linking tyrosine kinases to the mitogenic RAS pathway and recent reports suggest that its functions may be more complex (Bon®ni et al., 1996) . Indeed, SHC has been shown to bind dierent sets of proteins probably transducing more pleiotropic signals and our data suggest that, in FLT4L signaling, SHC mediates an inhibitory signal through its 239 and 240 tyrosines. Finally, with regard to VEGFR3/FLT4 role in angiogenesis, it may be interesting to further investigate a lead towards a potential means of control through negative regulation.
Materials and methods
Growth factors, antibodies and cell culture
Recombinant human CSF1 was purchased from Chiron (Cetus, St-Quentin-Yvelines, France) and Pepro Tech Inc. (TEBU, Le Perray-Yvelines, France). Anti phosphotyrosine monoclonal antibody (mAb) (4G10) and rabbit polyclonal anti SHC antibody were purchased from UBI (Lake Placid, NY, USA). Rabbit polyclonal anti GRB2 (C23) antibody, anti myc mAb (9E10) and rabbit polyclonal anti SOS 1/2 (D21) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A polyclonal anti FLT4 antibody was obtained by immunization of rabbits with a GST-FLT4 fusion protein containing the last 120 amino acids of FLT4L. GP+E and RAT2 cells were maintained in Dulbecco's Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY, USA) supplemented with 10% newborn serum (NBS). RAT2 cells expressing chimeric receptors were maintained in medium supplemented with G418 (1 mg/ml).
DNA constructs and expression vector
The FF4 (FMS-FLT4) chimeric molecules have been described elsewhere . The chimeric receptors cDNA were cloned into the retroviral vector LXSN containing a geneticin resistance marker.
Myc-tagged SHC has been previously described . The constructs SHC F198V, SHC R397K, SHC PTB+Y239/Y240 and SHC PTB were created by standard polymerase chain reaction (PCR) using murine p52 Shc cDNA (murine numbering of amino acids was thus used) as a template and appropriate oligonucleotides. The SHC tyrosine mutants SHC Y239F/Y240F, SHC Y313F and SHC Y3F (SHC Y239F/Y240/Y313F) were generated using the Transformer Mutagenesis Kit (Clontech). All constructs were subcloned into pBABE vector, a retroviral expression vector containing a puromycin resistance marker. All constructs were sequenced with T7 Sequencing kit (Pharmacia Biotech, Piscataway, NJ, USA).
Generation of retrivoris and retroviral infection
The retroviral packaging cell line GP+E was used for retrovirus production. GP+E cell transfections were performed on 2610 5 cells in 100 mm dishes using 25 mg of Lipofectin (Gibco ± BRL) and 10 mg of plasmid. Resistant cells were selected in complete medium containing 2 mg/ml of puromycin. RAT2 cells infection has been described (Fournier et al, 1995) . Four mg/ml of puromycin in complete medium were used to select infected RAT2 populations. Protein expressions were controlled by Western blot analysis.
